Navigation Links
NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
Date:9/13/2009

SAN DIEGO, Sept. 13 /PRNewswire/ -- NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA. The work was performed in collaboration with researchers at the Centers for Disease Control and Prevention (CDC), University of Hong Kong, and Saint Louis University.

DAS181 (Fludase(R)) is an investigational broad spectrum drug candidate being evaluated in human clinical development for treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza. Unlike neuraminidase inhibitors (NAI), e.g. Tamiflu(R), which directly target the influenza virus ("pathogen target"), DAS181 works by inactivating the human receptor ("host target") for these viruses; thus, it may be less likely to encounter acquired resistance compared with currently-available antiviral drugs. Extensive, prolonged nonclinical influenza studies have not shown the development of any meaningful resistance. This approach may have advantages over mono-therapy or combination therapy which directly target the pathogen. Previously announced preclinical studies conducted in collaboration with the CDC and others have shown DAS181 to have significant therapeutic and prophylactic activity in in vivo animal models and in human ex vivo lung tissue for a highly virulent H5N1 (A/VN/1203/04) strain of influenza.

A "Late Breaker" presentation, entitled "Novel Swine-Origin A (H1N1) Influenza Viruses are Potently Inhibited by DAS181, a Sialidase Fusion Protein" examined in vitro, ex vivo, and in vivo models to evaluate the activity of DAS181 against multiple human novel 2009 influenza A/H1N1 viruses (Novel H1N1 or "Swine Flu"). The data presented
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "MEMS Gyroscopes Analog Devices ADIS16136 Precision ... to their offering. ... grade applications made a lot of progress in ... They are now accepted in high-reliability environments, and ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... of Directors.  Dr. McKinnell is the former Chief Executive ... of Pfizer Inc.  He is currently Chairman of the ... infectious diseases in Africa, and is a member of ...
... and NEW YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ... Celtic Therapeutics ), a successor firm to Celtic Pharma, ... agreement under which Celtic Therapeutics has acquired and licensed ... for the treatment of dry eye syndrome and other ...
Cached Medicine Technology:Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 2Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 3Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 4Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a new weight ... co-founder of the Ace Medical Weight Loss Center in Rock ... look at the industry of weight loss, and how several ... and in television shows, however, she says the topic of ... played for basic laughs, which she believes impacts whether Americans ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Poor students get more fruits ... new study finds. But, the opposite is true for ... fruits and vegetables at school may give a healthy boost ... no matter what the family income level, students all ate ... study found. The study was published recently in the ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... depression resulting form multiple sclerosis had showed marked ... // The results of the investigation were reported ... Psychiatry. ,Although two-thirds of depressed patients prefer ... ever make a first appointment and nearly half ...
... the spread of gastrointestinal infections in the home. // ... families, which used the hand sanitizer in gel form, ... illness related to the gastrointestinal tract. ,Families ... Half the families were randomly assigned to receive hand ...
... high regard since the very old days and it continues ... recreation forms have been able to substitute mankind with another ... sudden death associated with exercise in young competitors. The benefits ... ,Recent medical research has reported that adolescents and ...
... elevate the role of fibres further by stating that ... plaque build-up in the arteries in postmenopausal women.// ... with a decreased risk of heart disease and death. ... fruit, and vegetables, and refined grain products on the ...
... said that the government would include Hepatitis B ... has been emerging as a "problem greater than ... Indian Council of Medical Research (ICMR)-World Health Organisation ... leptospirosis at the regional ICMR centre here, the ...
... Manoor Prakash Hande and his colleagues from National University ... risk of developing Chromosomal aberrations leading to cancer// in ... aimed at identifying biomarkers for easy detection and identification ... finding a link between complex chromosome aberrations and disease ...
Cached Medicine News:Health News:MS Patients Improve With Telephone Therapy 2Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Competitive Sports: Is the heart Sportive Enough? 2
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
... Hi-Mag takes us to the practical ... magnifier is often a 'last resort' ... visual acuities. The illuminated housing ensures ... to the battery handle by a ...
Medicine Products: